This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Phagelux, Inc., Wuhan Phagelux Bio-Tech Company Limited. Active years: 2018-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2020
Title: Innovations of Hang Yang in Biological Agents
Introduction
Hang Yang is an accomplished inventor based in Wuhan, China. He has made significant contributions to the field of biological agents, particularly through his innovative patents. With a total of 2 patents, his work focuses on developing lysins that target various bacterial infections.
Latest Patents
One of Hang Yang's latest patents is titled "Staphylococcus lysin and use thereof." This invention discloses a lysin capable of killing Staphylococcus species, including both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains. The lysin maintains activity across a wide pH range, specifically from pH 4 to 11. The recombinant protease constructed from the encoding gene can be solubly expressed in strain BL21 (DE3). This lysin can effectively kill multiple species in vitro and has potential applications as an antibiotic for treating staphylococcal infections in vivo. Additionally, it can rapidly lyse the staphylococcal cell wall, releasing intracellular substances such as ATP and DNA, which can be utilized for detection purposes.
Another notable patent involves a new lysin named ClyR, which is designed to target various species of Streptococci. Constructed using gene splicing methods, ClyR effectively kills different Streptococci and Enterococci. It exhibits good stability and is not sensitive to EDTA or high concentrations of NaCl. ClyR remains active in a pH range of 5 to 11 and is well expressed in strain BL21 (DE3). High doses of ClyR have shown no apparent toxicity in mice, and a single administration of 0.8 mg per mouse can completely protect against lethal doses of Group B Streptococci. This lysin has broad application prospects for controlling Streptococci infections.
Career Highlights
Hang Yang has worked with notable companies such as Wuhan Phagelux Bio-tech Company Limited and Phagelux, Inc. His innovative work in the field of biological agents has positioned him as a key figure in the development of new antibacterial treatments.
Collaborations
Hang Yang has collaborated with several professionals in his field, including Hongping Wei and Junping Yu. These collaborations have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile